Gabriel Brooks - 18 Oct 2024 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)

Role
Chief Medical Officer
Signature
/s/ David Tyronne Howton as attorney-in-fact for Gabriel Brooks
Issuer symbol
SLDB
Transactions as of
18 Oct 2024
Net transactions value
-$19,000
Form type
4
Filing time
22 Oct 2024, 16:05:03 UTC
Previous filing
16 Feb 2024
Next filing
11 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLDB Common Stock Options Exercise +9,750 +235% 13,902 18 Oct 2024 Direct F1, F2
transaction SLDB Common Stock Sale $19,000 -2,923 -21% $6.50 10,979 21 Oct 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLDB Restricted Stock Units Options Exercise $0 -9,750 -25% $0.000000 29,250 18 Oct 2024 Common Stock 9,750 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2 Includes 4,152 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 31, 2024.
F3 This sale was made to cover withholding taxes following the vesting of the previously granted RSUs.
F4 The RSUs were granted on October 18, 2023 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.